Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
REMSleep Holdings, Inc. (RMSL)
USD0.00
+0.00 (+1.52%)
US OTC Healthcare Medical - Devices
Address
2202 North West Shore Boulevard 33607
Tampa, FL, US
Tampa, FL, US
CEO
Jeffrey Marshall
Website
remsleeptech.com
IPO
2009-07-24
CIK 1412126 ISIN US75990A2006
Description
REMSleep Holdings, Inc. is an enterprise globally focused on crafting and providing solutions for individuals afflicted with sleep apnea. Among its key offerings is the DeltaWave CPAP interface device, specifically engineered to aid in the treatment of patients suffering from this condition. The company caters to a broad spectrum of clients, including home healthcare providers, independent sleep clinics, direct consumers, medical practitioners, group medical organizations, hospitals, and various professional medical associations. Its corporate headquarters are situated in Tampa, Florida.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.00
+0.00 (+1.52%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
-0.16
Float Shares
1.64B
Free Float %
96.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -20.13% | -34.21% | -34.21% | -64.29% | +16.28% | +47.06% | -76.19% | -78.99% | -87.75% | -99.88% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.00
DCF (Unlevered)
148.44
+6,356,950.7%
DCF (Levered)
120.11
+5,143,775.3%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Quality scores
Altman Z-Score
-151.86
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Devices: +11.2%-85.7%
-
EPS growth Medical - Devices: +28.5%— Q1'26: -100.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%-17,365.0%
-
EBIT margin Medical - Devices: +6.2%-15,740.7%
-
ROIC Medical - Devices: +3.3%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+6.2% Q1'26: +10.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-10,091.26× Q1'26: -0.02× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-10 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-06-09 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-06-08 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-06-05 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-06-04 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-06-03 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-06-02 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-06-01 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-507.48B
OE per share TTM
-323.68
Owner's Yield
-12,007,769.20%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
9,807,076.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
2
Total invested
388.00
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2025 Q4
Investors holding
2
+0 vs prev Q
New positions
0
Closed positions
0
Increased
0
Reduced
1
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | NORTH STAR ASSET MANAGEMENT INC | 200.0K +— (+0.0%) | 1.3K +970.0 (+285.3%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD0.02 -50.0% | 19 qtrs — |
| 2 | PROVIDENCE WEALTH ADVISORS, LLC | — -28.3K (-100.0%) | — -48.0 (-100.0%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD— | 4 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
4
Shares acquired
—
Shares disposed
3.50M
Cash buys
—
Cash sales
—
Net activity
-3,500,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2017-06-29 | WOOD TOM J | Director / Officer | — | D | Preferred A | 2,000,000 | 0.00 | — | 0 | — | ↗ |
| 2017-06-29 | BIRD RUSSELL FINLAY | Officer / 10% Owner | — | D | Preferred A | 1,500,000 | 0.00 | — | 0 | — | ↗ |
| 2012-04-18 | Sullivan Matthew | Director / Officer | — | D | COMMON STOCK, PAR VALUE $.001 | 0 | 0.00 | — | 18,119,617 | — | ↗ |
| 2012-04-18 | Brookes Thomas | Director / Officer | — | D | COMMON STOCK, PAR VALUE $.001 | 0 | 0.00 | — | 100,143,541 | — | ↗ |
| 2011-11-25 | Stead Ken | Director / Officer / 10% Owner | J-Other | A | Common Stock | 135,000,000 | 0.00 | — | 296,000,000 | — | ↗ |
| 2011-11-25 | KAT Exploration Inc. | 10% Owner | J-Other | A | Common Stock | 135,000,000 | 0.00 | — | 296,000,000 | — | ↗ |
| 2010-10-14 | BARNES DAVID M | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2010-09-10 | Thistle Walter Leslie | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2010-06-04 | KAT Exploration Inc. | 10% Owner | — | D | Shares of common stock, par value $0.001 per share | 0 | 0.00 | — | 161,000,000 | — | ↗ |
| 2010-04-28 | Stead Ken | Director / Officer / 10% Owner | — | D | Common Stock, par value $0.001 per share | 0 | 0.00 | — | 2,264,000 | — | ↗ |
| 2010-01-25 | DAVIS RONALD | Officer | P-Purchase | A | COMMON STOCK | 55,000 | 0.20 | 11.0K | 1,088,333 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-13.2K
Shares Outstanding
1.69B
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jonathan Lane | Vice President & Chief Technology Officer | 47.0K | male |
| Irina Veselinovic | Secretary | — | female |
| Jeffrey Marshall | CEO & Director | — | male |
| Peter Downey | Interim President | — | — |
| Sanja Pekovic | Chief Executive Officer | — | — |
| Teresita Rubio | Treasurer & Chairman | — | female |
ESG Rating
ESG Score History MEDICAL - DEVICES
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for RMSL
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
